LncRNA-NEF suppressed oxaliplatin resistance and epithelial-mesenchymal transition in colorectal cancer through epigenetically inactivating MEK/ERK signaling
- 13 February 2023
- journal article
- research article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 30 (6) , 855-865
Abstract
A major cause of oxaliplatin chemoresistance in colorectal cancer (CRC) is acquired epithelial-mesenchymal transition (EMT) in cancer cells, making the cancer cells easy to metastasis and recurrence. LncRNA Neighboring Enhancer of FOXA2 (lncRNA-NEF) has been characterized as a tumor suppressor to mediate cancer metastasis in multiple cancer types. However, whether it mediated the drug resistance remains unknown. In the present study, an oxaliplatin-resistant CRC cell line (SW620R) was established and lncRNA-NEF was obviously down-regulated in this resistant cell line. The further loss and gain-of-function studies demonstrated that this lncRNA suppressed oxaliplatin resistance as well as EMT programme in vitro and inhibited metastasis in vivo. Mechanistically, lncRNA-NEF epigenetically promoted the expression of DOK1 (Downstream of Tyrosine kinase 1), a negative regulator of MEK/ERK signaling, by disrupting DNA methyltransferases (DNMTs)-mediated DNA methylation. DOK1, in turn, induced the inactivation of MEK/ERK signaling, forming the lncRNA-NEF/DOK1/MEK/ERK regulatory axis to mediate oxaliplatin resistance in CRC. Collectively, our work reveals the critical function of lncRNA-NEF in mediating the oxaliplatin chemotherapy resistance in CRC, and provides a promising therapeutic strategy for CRC patients with oxaliplatin resistance.Keywords
Funding Information
- National Natural Science Foundation of China (81772404)
- Natural Science Foundation of Guangdong Province (2021A1515012111)
This publication has 49 references indexed in Scilit:
- Subcellular compartmentalization of docking protein-1 contributes to progression in colorectal cancerEBioMedicine, 2016
- ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP InhibitorsCancer Discovery, 2015
- HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathwayCancer Biology & Therapy, 2015
- Targeting RAS–ERK signalling in cancer: promises and challengesNature Reviews Drug Discovery, 2014
- Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trialsThe Lancet Oncology, 2014
- The role of tumour–stromal interactions in modifying drug response: challenges and opportunitiesNature Reviews Drug Discovery, 2013
- Inactivation of the putative suppressor gene DOK1 by promoter hypermethylation in primary human cancersInternational Journal of Cancer, 2011
- Identification of DOK genes as lung tumor suppressorsNature Genetics, 2010
- Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapyAnnals of Oncology, 2007
- Role of the rasGAP-associated docking protein p62dokin negative regulation of B cell receptor-mediated signalingGenes & Development, 2000